Ecto‐5′‐nucleotidase/CD73 enhances endothelial barrier function and sprouting in blood but not lymphatic vasculature
CD73/ecto‐5′‐nucleotidase is a key enzyme in the regulation of purinergic signaling and inflammatory reactions. It hydrolyzes extracellular AMP into adenosine, which dampens immune cell activation, and reduces leukocyte trafficking. By comparing CD73 expression and function in mononuclear and endothelial cells (ECs) of blood and lymph, we show that extracellular purines and CD73 activity have differential effects in these two vascular systems. We found that CD8‐positive T lymphocytes and CD19‐positive B lymphocytes in human lymph expressed high levels of CD73 and other purinergic enzymes and adenosine receptors. Soluble CD73 was less abundant in human lymph than in serum, whereas CD73 activity was higher in afferent lymphatic ECs than in blood ECs. Adenosine signaling improved barrier function and induced sprouting of human blood, but not lymphatic, ECs in vitro. Similarly, using CD73‐deficient mice we found that CD73 controls only blood vascular permeability at selected lymphoid organs under physiological conditions. Thus, both vascular and lymphatic arms of the immune system synthesize the components of purinergic signaling system, but surprisingly they use CD73 differentially to control endothelial permeability and sprouting..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2015 |
|---|---|
| Erschienen: |
2015 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:45 |
|---|---|
| Enthalten in: |
European journal of immunology - 45(2015), 2, Seite 562-573 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Yegutkin, Gennady G [VerfasserIn] |
|---|
| Links: |
Volltext |
|---|
| doi: |
10.1002/eji.201444856 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC1962968421 |
|---|
| LEADER | 01000caa a2200265 4500 | ||
|---|---|---|---|
| 001 | OLC1962968421 | ||
| 003 | DE-627 | ||
| 005 | 20230714160425.0 | ||
| 007 | tu | ||
| 008 | 160206s2015 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1002/eji.201444856 |2 doi | |
| 028 | 5 | 2 | |a PQ20160617 |
| 035 | |a (DE-627)OLC1962968421 | ||
| 035 | |a (DE-599)GBVOLC1962968421 | ||
| 035 | |a (PRQ)c2449-667de2029219a2c65b07f281266aede3b7f4f92184a3b5f790a291f7dfeebfb23 | ||
| 035 | |a (KEY)0011453720150000045000200562ecto5nucleotidasecd73enhancesendothelialbarrierfun | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q DNB |
| 100 | 1 | |a Yegutkin, Gennady G |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Ecto‐5′‐nucleotidase/CD73 enhances endothelial barrier function and sprouting in blood but not lymphatic vasculature |
| 264 | 1 | |c 2015 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 520 | |a CD73/ecto‐5′‐nucleotidase is a key enzyme in the regulation of purinergic signaling and inflammatory reactions. It hydrolyzes extracellular AMP into adenosine, which dampens immune cell activation, and reduces leukocyte trafficking. By comparing CD73 expression and function in mononuclear and endothelial cells (ECs) of blood and lymph, we show that extracellular purines and CD73 activity have differential effects in these two vascular systems. We found that CD8‐positive T lymphocytes and CD19‐positive B lymphocytes in human lymph expressed high levels of CD73 and other purinergic enzymes and adenosine receptors. Soluble CD73 was less abundant in human lymph than in serum, whereas CD73 activity was higher in afferent lymphatic ECs than in blood ECs. Adenosine signaling improved barrier function and induced sprouting of human blood, but not lymphatic, ECs in vitro. Similarly, using CD73‐deficient mice we found that CD73 controls only blood vascular permeability at selected lymphoid organs under physiological conditions. Thus, both vascular and lymphatic arms of the immune system synthesize the components of purinergic signaling system, but surprisingly they use CD73 differentially to control endothelial permeability and sprouting. | ||
| 540 | |a Nutzungsrecht: © 2014 WILEY‐VCH Verlag GmbH & Co. KGaA, Weinheim | ||
| 540 | |a © 2014 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim. | ||
| 650 | 4 | |a endothelial cells | |
| 650 | 4 | |a adenosine | |
| 650 | 4 | |a lymphatics | |
| 650 | 4 | |a purinergic signaling | |
| 650 | 4 | |a permeability | |
| 650 | 4 | |a Receptors, Purinergic P1 - genetics | |
| 650 | 4 | |a Endothelium, Lymphatic - metabolism | |
| 650 | 4 | |a Endothelium, Lymphatic - cytology | |
| 650 | 4 | |a CD8-Positive T-Lymphocytes - metabolism | |
| 650 | 4 | |a Adenosine - metabolism | |
| 650 | 4 | |a 5'-Nucleotidase - immunology | |
| 650 | 4 | |a Antigens, CD19 - immunology | |
| 650 | 4 | |a Adenosine - immunology | |
| 650 | 4 | |a Endothelium, Vascular - immunology | |
| 650 | 4 | |a 5'-Nucleotidase - deficiency | |
| 650 | 4 | |a Endothelium, Vascular - metabolism | |
| 650 | 4 | |a Antigens, CD19 - genetics | |
| 650 | 4 | |a Endothelial Cells - cytology | |
| 650 | 4 | |a B-Lymphocytes - immunology | |
| 650 | 4 | |a Endothelium, Lymphatic - immunology | |
| 650 | 4 | |a Capillary Permeability - immunology | |
| 650 | 4 | |a CD8-Positive T-Lymphocytes - immunology | |
| 650 | 4 | |a Endothelium, Vascular - cytology | |
| 650 | 4 | |a Receptors, Purinergic P1 - immunology | |
| 650 | 4 | |a Adenosine Monophosphate - metabolism | |
| 650 | 4 | |a 5'-Nucleotidase - genetics | |
| 650 | 4 | |a Endothelial Cells - metabolism | |
| 650 | 4 | |a B-Lymphocytes - cytology | |
| 650 | 4 | |a CD8-Positive T-Lymphocytes - cytology | |
| 650 | 4 | |a Adenosine Monophosphate - immunology | |
| 650 | 4 | |a B-Lymphocytes - metabolism | |
| 650 | 4 | |a Endothelial Cells - immunology | |
| 650 | 4 | |a Blood | |
| 650 | 4 | |a Permeability | |
| 650 | 4 | |a Adenosine | |
| 650 | 4 | |a Rodents | |
| 650 | 4 | |a Immune system | |
| 700 | 1 | |a Auvinen, Kaisa |4 oth | |
| 700 | 1 | |a Rantakari, Pia |4 oth | |
| 700 | 1 | |a Hollmén, Maija |4 oth | |
| 700 | 1 | |a Karikoski, Marika |4 oth | |
| 700 | 1 | |a Grénman, Reidar |4 oth | |
| 700 | 1 | |a Elima, Kati |4 oth | |
| 700 | 1 | |a Jalkanen, Sirpa |4 oth | |
| 700 | 1 | |a Salmi, Marko |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of immunology |d Weinheim : Wiley, 1971 |g 45(2015), 2, Seite 562-573 |w (DE-627)129288713 |w (DE-600)120108-6 |w (DE-576)014470306 |x 0014-2980 |7 nnns |
| 773 | 1 | 8 | |g volume:45 |g year:2015 |g number:2 |g pages:562-573 |
| 856 | 4 | 1 | |u http://dx.doi.org/10.1002/eji.201444856 |3 Volltext |
| 856 | 4 | 2 | |u http://onlinelibrary.wiley.com/doi/10.1002/eji.201444856/abstract |
| 856 | 4 | 2 | |u http://www.ncbi.nlm.nih.gov/pubmed/25402681 |
| 856 | 4 | 2 | |u http://search.proquest.com/docview/1652326960 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OLC-DE-84 | ||
| 912 | |a GBV_ILN_48 | ||
| 912 | |a GBV_ILN_267 | ||
| 912 | |a GBV_ILN_2004 | ||
| 912 | |a GBV_ILN_2005 | ||
| 912 | |a GBV_ILN_2018 | ||
| 912 | |a GBV_ILN_2219 | ||
| 912 | |a GBV_ILN_4012 | ||
| 912 | |a GBV_ILN_4219 | ||
| 951 | |a AR | ||
| 952 | |d 45 |j 2015 |e 2 |h 562-573 | ||